NIC-0102

• Description :

  NIC-0102 is an orally active proteasome inhibitor (pIC50=7.55) that specifically inhibits NLRP3 inflammatory vesicle activation. NIC-0102 shows potent anti-inflammatory effects in a model of dextran sulfate sodium (DSS) -induced ulcerative colitis. NIC-0102 also inhibits production of pro-IL-1β[1].

• UNSPSC :

  12352005

• Target :

  NOD-like Receptor (NLR) ; Proteasome

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation; Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/nic-0102.html

• Purity :

  98.72

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  CC(C[C@@H](B(O)O)NC([C@@H](NC(C1=C(C=CC=C1F)F)=O)CC2=CC=CC=C2)=O)C

• Molecular Formula :

  C21H25BF2N2O4

• Molecular Weight :

  418.24

• References & Citations :

  [1]Wu X, et al. Discovery of a Novel Oral Proteasome Inhibitor to Block NLRP3 Inflammasome Activation with Anti-inflammation Activity. J Med Chem. 2022 Sep 5.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2806031-94-5]